Lakefront Biotherapeutics (LKFT) Cash from Investing Activities Growth (3y) (2018 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Cash from Investing Activities Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -44.69% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -39.73% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -246.81% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -53.57% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.84% |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 30.69% |
| Dec 31, 2025 | 27.37% |
| Mar 31, 2025 | 27.75% |
| Jun 30, 2024 | -31.32% |
| Mar 31, 2024 | -62.33% |
| Mar 31, 2023 | -32.04% |
| Dec 31, 2022 | 32.69% |
| Mar 31, 2022 | -547.33% |
| Jun 30, 2021 | 341.12% |
| Mar 31, 2021 | 585.81% |
| Jun 30, 2020 | -27.01% |
| Mar 31, 2020 | 459.59% |
| Dec 31, 2019 | -709.08% |
| Jun 30, 2019 | -38.36% |
| Mar 31, 2019 | -49.40% |
| Dec 31, 2018 | -56.82% |